Epilepsy Therapeutics
1. Aptiom patent expiration
Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures; Treatment of partial-onset seizures in patients with
APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5753646 | SUMITOMO PHARMA AM | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
Jun, 2021
(4 years ago) | |
| US9206135 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750747 | SUMITOMO PHARMA AM | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(6 years from now) | |
| US10702536 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US9763954 | SUMITOMO PHARMA AM | Therapeutical uses of eslicarbazepine |
Sep, 2028
(2 years from now) | |
| US10695354 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US10675287 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US11364247 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US9643929 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 months from now) | |
| US9566244 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(2 years from now) | |
| US10912781 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(2 years from now) | |
| US8372431 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Dosage: TABLET
How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage
APTIOM family patents
2. Briviact patent expiration
Treatment: Treatment of partial-onset seizures in patients 4 years of age and older; Treatment of partial onset seizures in patients with epilepsy aged...
BRIVIACT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6784197 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(4 years ago) | |
| US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(a month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492416 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(4 years ago) | |
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
| New Patient Population(NPP) | Aug 27, 2024 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Dosage: TABLET; SOLUTION
How can I launch a generic of BRIVIACT before it's drug patent expiration?
More Information on Dosage
BRIVIACT family patents
3. Epidiolex patent
expiration
Treatment: Use for the treatment of focal seizures in patients with dravet syndrome; Use for reducing convulsive seizure frequency in patients with dravet syndrome; Use for the treatment of atonic seizures in pa...
EPIDIOLEX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10195159 | JAZZ PHARMS RES | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May, 2022
(3 years ago) | |
| US11207292 | JAZZ PHARMS RES | Cannabidiol preparations and its uses |
Apr, 2039
(13 years from now) | |
| US11096905 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US11865102 | JAZZ PHARMS RES | Cannabidiol preparations and its uses |
Apr, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357741 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10603288 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10111840 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956186 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10092525 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9949937 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11633369 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956183 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956184 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11963937 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956185 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10709671 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11766411 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10137095 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US12102619 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(15 years from now) | |
| US10709674 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US12064399 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11065209 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US11160795 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(15 years from now) | |
| US11154516 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10849860 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11311498 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10918608 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US10966939 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11406623 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(15 years from now) | |
| US11400055 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US11446258 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11701330 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10709673 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 31, 2023 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| M(M-270) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Dosage: SOLUTION
How can I launch a generic of EPIDIOLEX before it's drug patent expiration?
More Information on Dosage
EPIDIOLEX family patents
4. Fintepla patent expiration
Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and...
FINTEPLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10947183 | UCB INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10950331 | UCB INC | Control system for control of distribution of medication |
Sep, 2035
(9 years from now) | |
|
US11759440 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US11406606 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US9603815 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(7 years from now) | |
|
US10950331 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Mar, 2036
(10 years from now) | |
|
US9549909 (Pediatric) | UCB INC | Method for the treatment of dravet syndrome |
Nov, 2033
(7 years from now) | |
|
US10452815 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Dec, 2038
(12 years from now) | |
|
US9610260 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(7 years from now) | |
|
US9603814 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(7 years from now) | |
|
US10603290 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US10478442 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(7 years from now) | |
|
US10478441 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(7 years from now) | |
|
US11040018 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US12097206 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(7 years from now) | |
|
US11786487 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US10947183 (Pediatric) | UCB INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(11 years from now) | |
| US9603815 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(7 years from now) | |
| US9549909 | UCB INC | Method for the treatment of dravet syndrome |
May, 2033
(7 years from now) | |
| US10452815 | UCB INC | Control system for control of distribution of medication |
Jun, 2038
(12 years from now) | |
| US9610260 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(7 years from now) | |
| US9603814 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(7 years from now) | |
| US10478442 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(7 years from now) | |
| US10478441 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(7 years from now) | |
| US12097206 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(7 years from now) | |
| US11759440 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US11406606 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US11786487 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US10603290 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US11040018 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 25, 2023 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Dosage: SOLUTION
How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage
FINTEPLA family patents
5. Journavx patent expiration
Treatment: Treatment of moderate to severe acute pain in adults using suzetrigine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11834441 | VERTEX PHARMS INC | Substituted tetrahydrofurans as modulators of sodium channels |
Dec, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2030 |
Drugs and Companies using SUZETRIGINE ingredient
NCE-1 date: 30 January, 2029
Market Authorisation Date: 30 January, 2025
Dosage: TABLET
More Information on Dosage
JOURNAVX family patents
6. Keppra patent expiration
Treatment: NA
KEPPRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(5 years from now) | |
|
US8802142 (Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 06 January, 2006
Dosage: TABLET
How can I launch a generic of KEPPRA before it's drug patent expiration?
More Information on Dosage
KEPPRA family patents
7. Lyrica patent expiration
Treatment: Management of fibromyalgia; Treatment of seizure disorder; Treatment of pain, including neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, postherpetic neuralgia, a...
LYRICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(7 years ago) | |
| US6001876 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
|
US6001876 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| US5563175 | UPJOHN | GABA and L-glutamic acid analogs for antiseizure treatment |
Oct, 2013
(12 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(6 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-651) | Jun 20, 2015 |
| M(M-193) | Dec 22, 2019 |
| New Patient Population(NPP) | May 23, 2022 |
| Pediatric Exclusivity(PED) | Nov 23, 2022 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 30 December, 2004
Dosage: CAPSULE; SOLUTION
How can I launch a generic of LYRICA before it's drug patent expiration?
More Information on Dosage
LYRICA family patents
8. Trileptal patent expiration
Treatment: Method of treating seizures
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7037525 | NOVARTIS | Oxacarbazepine film-coated tablets |
Feb, 2018
(7 years ago) | |
|
US8119148 (Pediatric) | NOVARTIS | Suspension comprising oxcarbazepine |
Jun, 2021
(4 years ago) | |
|
US7037525 (Pediatric) | NOVARTIS | Oxacarbazepine film-coated tablets |
Aug, 2018
(7 years ago) | |
| US8119148 | NOVARTIS | Suspension comprising oxcarbazepine |
Dec, 2020
(5 years ago) | |
Drugs and Companies using OXCARBAZEPINE ingredient
Market Authorisation Date: 25 May, 2001
Dosage: SUSPENSION; TABLET
How can I launch a generic of TRILEPTAL before it's drug patent expiration?
More Information on Dosage
TRILEPTAL family patents
9. Vimpat patent expiration
Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older; Method of treating, as...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5654301 | UCB INC | Amino acid derivative anticonvulsant |
Aug, 2014
(11 years ago) | |
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2013 |
| New Dosing Schedule(D-143) | Aug 29, 2017 |
| New Dosing Schedule(D-144) | Aug 29, 2017 |
| New Indication(I-696) | Aug 29, 2017 |
| M(M-217) | Nov 03, 2020 |
| New Indication(I-878) | Nov 16, 2023 |
| New Patient Population(NPP) | Oct 14, 2024 |
| New Dosing Schedule(D-188) | Apr 28, 2026 |
Drugs and Companies using LACOSAMIDE ingredient
NCE-1 date: 28 October, 2012
Market Authorisation Date: 28 October, 2008
Dosage: TABLET; SOLUTION
How can I launch a generic of VIMPAT before it's drug patent expiration?
More Information on Dosage
VIMPAT family patents
10. Xcopri patent expiration
Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598279 | SK LIFE | Neurotherapeutic azole compounds |
Oct, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654133 | SK LIFE | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: 10 March, 2024
Market Authorisation Date: 10 March, 2020
Dosage: TABLET
More Information on Dosage
XCOPRI family patents
11. Ztalmy patent expiration
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older; Treatment of seizures associated with cyclin-dependent kina...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US12115169 | MARINUS | NA |
Sep, 2042
(16 years from now) | |
| US12268696 | MARINUS | NA |
Sep, 2042
(16 years from now) | |
| US12144801 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(11 years from now) | |
| US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(11 years from now) | |
| US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
| Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Dosage: SUSPENSION
More Information on Dosage
ZTALMY family patents